Actively Recruiting
A Study Evaluating Hyperpolarized 129 Xenon Magnetic Resonance Imaging in Subjects With Chronic Lung Disease
Led by Western University, Canada · Updated on 2024-06-13
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating new imaging techniques in adults aged 18 to 85 with lung diseases such as asthma, emphysema, COPD, bronchiectasis, sarcoidosis, pulmonary fibrosis, alpha 1-anti-trypsin deficiency, and lymphangioleiomyomatosis (LAM). The study aims to develop tools for analyzing lung function and structure using hyperpolarized Xenon 129 MRI alongside pulmonary function tests. This research is supported by Western University, Canada. Participants will undergo a series of tests during a one to two-hour visit, including medical history review, vital signs measurement, full pulmonary function testing following American Thoracic Society guidelines, proton MRI, specialized 129-Xe MRI scans using chest coils, and a low-dose thoracic CT scan. The MRI procedure includes monitoring heart rate and oxygen levels, providing hearing protection, and offering supplemental oxygen as needed. These imaging and testing methods help assess lung ventilation, diffusion, and gas exchange. During the study visit, participants will complete pulmonary function tests such as spirometry, plethysmography, and diffusing capacity tests. They will undergo magnetic resonance imaging with hyperpolarized Xenon gas to visualize lung airways and anatomy, along with CT scans matched to MRI breathing maneuvers. Researchers will measure ventilation defect percent (VDP), apparent diffusion coefficients (ADC), and dissolved phase spectroscopy over five years. Participant safety is monitored throughout the visit, and the total study duration includes these assessments and follow-up measures.
CONDITIONS
Brief Title
129 Xenon MRI in Chronic Lung Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 to 85 years
- Diagnosed with lung disease such as asthma, emphysema, COPD, bronchiectasis, sarcoidosis, pulmonary fibrosis, alpha 1-anti-trypsin deficiency, or lymphangioleiomyomatosis (LAM)
- Able to understand study procedures and provide informed consent
- Able to hold breath for 16 seconds
- Judged to be in stable health based on medical history
- Able to perform reproducible pulmonary function tests
- Forced Expiratory Volume in one second (FEV1) greater than 25% predicted
- Forced Vital Capacity (FVC) greater than 25% predicted and over 0.5 liters
You will not qualify if you...
- Mentally or legally incapacitated or unable to understand study materials
- Daytime room air oxygen saturation less than or equal to 92% while lying down
- Unable to perform spirometry or plethysmography tests
- Unable to tolerate MRI due to size or claustrophobia
- Pregnant or breastfeeding
- Presence of MRI incompatible devices or metal that cannot be removed, including pacemakers, neurostimulators, insulin pumps, aneurysm clips, bioprostheses, artificial limbs, metallic fragments, shunts, surgical staples, or ear implants
- Any physical or psychological condition preventing MRI performance, such as severe claustrophobia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 to 2 hours
Participants undergo pulmonary function tests, proton MRI, hyperpolarized 129 Xenon MRI, and low-dose thoracic CT to assess lung structure and function.
1 visit (in-person)
Duration - Up to 5 years
Participants will be monitored over 5 years with repeated hyperpolarized Xenon MRI and pulmonary function tests to evaluate lung ventilation and structure.
Visits at baseline and over time as scheduled
Trial Site Locations
Total: 1 location
1
Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre
London, Ontario, Canada, N6A 5B7
Actively Recruiting
Research Team
G
Grace E Parraga, PhD
A
Angela P Wilson, RRT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here